PROJECT 1 : Molecular Genetics Chronic lymphocytic leukemia (CLL), an incurable disease that affects individuals over 50 years of age, is the most common leukemia in the Western World. At present, the clinical approach to the treatment of CLL is "wait and watch" because in most cases the disease is indolent, often for long periods of time, although with time it may transform into an aggressive disease. Thus, it may be counterproductive to treat a disease that may remain indolent for long periods of time with aggressive chemo/immunotherapy. On the contrary, the aggressive form of CLL, that involves approximately 20-30% of patients, is a malignant disease with poor prognosis that should be treated promptly and aggressively. During the past few years, with the support of this grant and of interactions and collaborations with investigators of the other projects, we have discovered the fundamental genetic changes responsible for the indolent and aggressive forms of CLL. We were. also able to develop mouse models for both the aggressive and indolent forms of CLL. Recently we have compared the microRNA expression profiles in samples obtained from CLL patients that have remained indolent for many years, to samples obtained from CLL patients that were indolent but became aggressive with time and we have identified specific changes in microRNA expression that correlate with the malignant progression. In this renewal application, we intend unravel the fundamental changes that convert an indolent to an aggressive disease by the following aims:
AIM #1 Detection of the genome-wide microRNA alterations during the progression of CLL AIM #2 Studies of the molecular networks controlled by the altered microRNAs AIM #3 Identification of the factors promoting microRNAs dysregulation during the progression of CLL We also plan to exploit the mouse models we have developed with this grant support to unravel the mechanisms involved in tumor progression, thus facilitating an understanding of the progression of human CLL.
Chronic lymphocytic leukemia (CLL) is the most common leukemia of the Western World and is incurable. We propose to identify targets that can be exploited for the development of innovative therapy for the cure and prevention of this disease.
|Mani, R; Mao, Y; Frissora, F W et al. (2015) Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia. Leukemia 29:346-55|
|Veronese, A; Pepe, F; Chiacchia, J et al. (2015) Allele-specific loss and transcription of the miR-15a/16-1 cluster in chronic lymphocytic leukemia. Leukemia 29:86-95|
|Woyach, Jennifer A; Furman, Richard R; Liu, Ta-Ming et al. (2014) Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med 370:2286-94|
|Chen, Wenbing; Han, Yanyan; Peng, Xiaohua (2014) Aromatic nitrogen mustard-based prodrugs: activity, selectivity, and the mechanism of DNA cross-linking. Chemistry 20:7410-8|
|Stephens, D M; Ruppert, A S; Jones, J A et al. (2014) Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single center. Leukemia 28:1365-8|
|Cheney, Carolyn M; Stephens, Deborah M; Mo, Xiaokui et al. (2014) Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia. MAbs 6:749-55|
|Strati, Paolo; Ferrajoli, Alessandra; Lerner, Susan et al. (2014) Fludarabine, cyclophosphamide and rituximab plus granulocyte macrophage colony-stimulating factor as frontline treatment for patients with chronic lymphocytic leukemia. Leuk Lymphoma 55:828-33|
|Cui, Bing; Chen, Liguang; Zhang, Suping et al. (2014) MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. Blood 124:546-54|
|Riches, John C; Gribben, John G (2014) Hanging tough: CMV-specific CD8+ T cells in CLL. Blood 123:608-9|
|Fecteau, Jessie-F; Corral, Laura G; Ghia, Emanuela M et al. (2014) Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53. Blood 124:1637-44|
Showing the most recent 10 out of 227 publications